Literature DB >> 15274098

Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis.

Pamela B Davis1, Mark D Schluchter, Michael W Konstan.   

Abstract

In cystic fibrosis (CF), sweat chloride concentration has been proposed as an index of CFTR function for testing systemic drugs designed to activate mutant CFTR. This suggestion arises from the assumption that greater residual CFTR function should lead to a lower sweat chloride concentration, as well as protection against severe lung disease. This logic gives rise to the hypothesis that the lower the sweat chloride concentration, the less severe the lung disease. In order to test this hypothesis, we studied 230 patients homozygous for the DeltaF508 allele, and 34 patients with at least one allele associated with pancreatic sufficiency, born since January 1, 1955, who have pulmonary function data and sweat chloride concentrations recorded in our CF center database, and no culture positive for B. cepacia. We calculated a severity index for pulmonary disease, using an approach which takes into account all available pulmonary function data as well as the patient's current age and survival status. Patients with alleles associated with pancreatic sufficiency had significantly better survival (P = 0.0083), lower sweat chloride concentration (81.4 +/- 23.8 vs. 103.2 +/- 14.2 mEq/l, P < 0.0001), slower rate of decline of FEV(1) % predicted (-0.75 +/- 0.34 vs. -2.34 +/- 0.17% predicted per year), and a better severity index than patients homozygous for the DeltaF508 allele (median 73rd percentile vs. median 55th percentile, P = 0.0004). However, the sweat chloride concentration did not correlate with the severity index, either in the population as a whole, or in the population of patients with alleles associated with pancreatic sufficiency, who are thought to have some residual CFTR function. These data suggest that, by itself, sweat chloride concentration does not necessarily predict a milder pulmonary course in patients with cystic fibrosis. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274098     DOI: 10.1002/ppul.20054

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  9 in total

Review 1.  Genetic variation and clinical heterogeneity in cystic fibrosis.

Authors:  Mitchell L Drumm; Assem G Ziady; Pamela B Davis
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

Review 2.  Ivacaftor: a novel mutation modulating drug.

Authors:  Harit Kapoor; Astha Koolwal; Ankur Singh
Journal:  J Clin Diagn Res       Date:  2014-11-20

3.  In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.

Authors:  Meghan E McGarry; Beate Illek; Ngoc P Ly; Lorna Zlock; Sabrina Olshansky; Courtney Moreno; Walter E Finkbeiner; Dennis W Nielson
Journal:  Pediatr Pulmonol       Date:  2017-01-09

4.  Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency.

Authors:  R Sebro; H Levy; K Schneck; D Dimmock; B A Raby; C L Cannon; U Broeckel; N J Risch
Journal:  Clin Genet       Date:  2011-11-29       Impact factor: 4.438

Review 5.  Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?

Authors:  E K Schneider; F Reyes-Ortega; J Li; T Velkov
Journal:  Clin Pharmacol Ther       Date:  2016-11-23       Impact factor: 6.875

Review 6.  Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.

Authors:  Steven M Rowe; Frank Accurso; John P Clancy
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 7.  Potential for therapeutic manipulation of the UPR in disease.

Authors:  Sang Won Park; Umut Ozcan
Journal:  Semin Immunopathol       Date:  2013-04-10       Impact factor: 9.623

8.  Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.

Authors:  Danya Muilwijk; Eyleen de Poel; Peter van Mourik; Sylvia W F Suen; Annelotte M Vonk; Jesse E Brunsveld; Evelien Kruisselbrink; Hugo Oppelaar; Marne C Hagemeijer; Gitte Berkers; Karin M de Winter-de Groot; Sabine Heida-Michel; Stephan R Jans; Hannah van Panhuis; Menno M van der Eerden; Renske van der Meer; Jolt Roukema; Edward Dompeling; Els J M Weersink; Gerard H Koppelman; Robert Vries; Domenique D Zomer-van Ommen; Marinus J C Eijkemans; Cornelis K van der Ent; Jeffrey M Beekman
Journal:  Eur Respir J       Date:  2022-08-18       Impact factor: 33.795

Review 9.  Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.

Authors:  Ruth O'Reilly; Heather E Elphick
Journal:  Drug Des Devel Ther       Date:  2013-08-30       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.